ASCO 2026 | Phase II study of FID-007 plus cetuximab in recurrent or metastatic HNSCC
Jacob Thomas, MD, of the University of Southern California, discusses findings from a Phase II trial (NCT06332092) evaluating FID-007, a novel nanoparticle paclitaxel formulation, in combination with cetuximab for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) following checkpoint inhibitor therapy. Dr Thomas highlights promising response rates and durable complete responses observed in this early study. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This study is looking at patients who have progressed after a checkpoint inhibitor in the relapsed metastatic setting. And currently the standard of care is either cetuximab or perhaps other cytotoxic chemotherapies such as taxanes. So what this study showed is that this combination of cetuximab with FID-007, which is a novel nanoparticle paclitaxel formulation, is highly active in recurrent metastatic head and neck squamous cell cancer patients who have progressed on prior checkpoint inhibitor therapy...
This study is looking at patients who have progressed after a checkpoint inhibitor in the relapsed metastatic setting. And currently the standard of care is either cetuximab or perhaps other cytotoxic chemotherapies such as taxanes. So what this study showed is that this combination of cetuximab with FID-007, which is a novel nanoparticle paclitaxel formulation, is highly active in recurrent metastatic head and neck squamous cell cancer patients who have progressed on prior checkpoint inhibitor therapy. So we’re seeing high response rates, including high complete response rates and which are durable and so further study is needed again this is a small study but based on these promising results we’re looking at developing a phase three
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
